Symdeko
Active Ingredient(s): Ivacaftor + TezacaftorFDA Approved: * February 12, 2018
Pharm Company: * VERTEX PHARMS INC
Category: Genetic Disorders
Tezacaftor is a drug used for the treatment of cystic fibrosis (CF) in people six years and older, who have a F508del mutation, the most common type of mutation in the CFTR gene .[1][2] It is sold as a fixed-dose combination with ivacaftor under the brand name Symdeko.[3][4][5] It was approved by the U.S. FDA in 2018.[1] The combination of elexacaftor, tezacaftor, and ivacaftor is being sold as Tr... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.